NASDAQ:LGND Ligand Pharmaceuticals Q3 2026 Earnings Date & Estimates $297.28 +1.74 (+0.59%) Closing price 04:00 PM EasternExtended Trading$296.73 -0.55 (-0.19%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Ligand Pharmaceuticals is estimated to report Q3 2026 earnings on Thursday, October 29, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateOctober 29, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Ligand Pharmaceuticals in Q3 2026Ligand Pharmaceuticals is expected to post earnings of $2.26 per share on revenue of $77.95 million. In the same quarter a year earlier Ligand Pharmaceuticals reported $3.09 per share on revenue of $86.89 million. Ligand Pharmaceuticals last reported on August 6, 2026, posting $2.37 per share and beating the $1.97 consensus estimate. Ligand Pharmaceuticals has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS$2.26Expected Revenue$77.95 millionPrior-Year EPS$3.09Prior-Year Revenue$86.89 millionExpected EPS Growth-26.9%Expected Revenue Growth-10.3%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$2.37 (Beat by +$0.40)Last Quarter Revenue$63.69 millionEPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Ligand Pharmaceuticals Q3 2026 Earnings FAQ When does Ligand Pharmaceuticals report Q3 2026 earnings? Ligand Pharmaceuticals (NASDAQ:LGND) is estimated to report Q3 2026 earnings on Thursday, October 29, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Ligand Pharmaceuticals' Q3 2026 earnings call? Ligand Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, October 29, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Ligand Pharmaceuticals? Analysts expect Ligand Pharmaceuticals to post earnings of $2.26 per share for Q3 2026. How much revenue is Ligand Pharmaceuticals expected to report? The consensus revenue estimate for Ligand Pharmaceuticals is $77.95 million for Q3 2026. Ligand Pharmaceuticals Earnings HeadlinesLigand to Report Third Quarter 2026 Financial Results on October 29, 2026October 15, 2026 | globenewswire.comIs Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook?September 29, 2026 | finance.yahoo.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 19 at 1:00 AM | Investors Alley (Ad)Ligand Joins with AvenCell, Shares DownSeptember 25, 2026 | baystreet.caAnalysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Ligand Pharma (LGND) and Compass Therapeutics (CMPX)September 25, 2026 | theglobeandmail.comLigand Commits Upto $47 Mln To AvenCell Cancer Cell TherapySeptember 24, 2026 | rttnews.comSee More Ligand Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ligand Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ligand Pharmaceuticals and other key companies, straight to your email. Email Address About Ligand PharmaceuticalsLigand Pharmaceuticals (NASDAQ:LGND) (NASDAQ: LGND) is a biopharmaceutical company that develops, acquires and licenses technologies intended to improve the development and commercialization of medicines. Rather than operating primarily as a traditional drug manufacturer, Ligand generally works with pharmaceutical and biotechnology partners, receiving licensing payments, royalties and other consideration tied to partnered products. The company’s principal technology is Captisol, a modified cyclodextrin designed to improve the solubility, stability and delivery of certain active pharmaceutical ingredients. Captisol is used in several approved medicines developed by partners, including products in oncology and other therapeutic areas. Ligand also has interests in a portfolio of proprietary drug-development programs and other enabling technologies spanning areas such as cancer, infectious diseases, immunology and rare diseases. Founded in 1987, Ligand has built its business through internal research, acquisitions and licensing agreements with pharmaceutical companies and biotechnology firms. Its technologies and partnered products serve international markets through licensees and commercial partners, giving the company a global presence without relying solely on its own sales infrastructure.View Ligand Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Tesla's Roadster Reveal Hints at 2 Much Bigger MovesThe AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance AnywayRate-Resilient vs. Rate-Exposed: Why Homebuilder Stocks Are DivergingMarketBeat Week in Review – 10/12 - 10/16Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?Could a Trucking Squeeze Become J.B. Hunt’s Biggest Edge?Meta Claims Frontier-Class AI Status With New Muse Wonder Models Upcoming Earnings America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026)Northrop Grumman (10/20/2026)RTX (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
